

A Rare Case of Facioscapulo Humeral Muscular Dystrophy

¹Dr. M.B. Lingayat, ²Dr. Arpit Kumar Kesharwani, ³Dr. Abdullah Ansari, ⁴Dr. Aman Sangai, ⁵Dr. Arvind Kumar, ⁶Dr. Venkatesh Bhandari

¹⁻⁶Government Medical College, Aurangabad

Corresponding Author: Dr. Arpit Kumar Kesharwani, Government Medical College, Aurangabad

How to citation this article: Dr. M.B. Lingayat, Dr. Arpit Kumar Kesharwani, Dr. Abdullah Ansari, Dr. Aman Sangai, Dr. Arvind Kumar, Dr. Venkatesh Bhandari, “A Rare Case of Facioscapulo Humeral Muscular Dystrophy”, IJMACR- April - 2024, Volume – 7, Issue - 2, P. No. 44 – 46.

Open Access Article: © 2024, Dr. Arpit Kumar Kesharwani, et al. This is an open access journal and article distributed under the terms of the creative common’s attribution license (<http://creativecommons.org/licenses/by/4.0>). Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Type of Publication: Case Report

Conflicts of Interest: Nil

Abstract

Facioscapulo humeral muscular dystrophy (FSHD) is a rare type of myopathy and differs clinically and genetically from Duchene muscular dystrophy. We present a case of (FSHD) in a 30 years old male. Contrary to the typical autosomal dominant inheritance pattern, this case appears sporadic in nature. FSHD usually manifests in adolescence, and while the condition predominantly affects the face, its slow progression means symptoms may also be observable in children.

Keywords: Facioscapulo Humeral Muscular Dystrophy, Myopathy, Autosomal Dominant Disorder

Introduction

Facioscapulo humeral muscular dystrophy (FSHD) is a rare form of muscular dystrophy with an estimated prevalence from 1/8000 to 1/20000, inherited in autosomal dominant manner (1). The vast majority of FSHD patients exhibit deletions in the subtelomeric

repeat array known as D4Z4, located on chromosome 4q35. While normal individuals possess between 11 to 150 repeats of this array, FSHD patients typically have fewer than 11(2,3). Interestingly, these deletions do not appear to disrupt any identifiable gene. Rather, they cause the telomere to be positioned closer to the centromere, indirectly affecting the expression of neighboring genes. The exact mechanism underlying the disease remains unknown, but it is speculated to involve aberrant chromatin interactions at the nuclear envelope. Somatic mosaicism may be prevalent, particularly in de novo cases. Herein, we present a case of FSHD in a 30 yrs old male with no prior family history of the condition. He started to experience difficulty to maintain erect posture since 6 years which progressed gradually over time till today.

Case report

A 30 yrs old gentleman presented with history of weakness in arms and face with difficulty in maintaining

erect posture since 6 years. There was no history of fever, pains, paraesthesia or any trauma in the past with negative family history.

On examination he was well built, normotensive with normal general physical examinations. CNS examination showed normal mental function and fundus examination was also normal. He has bilateral facial weakness with bilateral sensory neural hearing loss, he has exaggerated lordotic attitude while standing and walking with difficulty in getting up from floor. There is marked shoulder muscle wasting and winging of scapula more on left side and prominence of scapula was more evident when he tried to push against the wall with elbows extended and hands at shoulder level. (Fig1&2)



Fig.1 Facial weakness with difficulty in pouting and smile.

His investigations revealed normal hemogram with normal liver and kidney function, his total CPK was raised 199 units per liter. EMG was done which showed myopathic pattern (Fig 3). Muscle biopsy showed features of myopathy with paraspinous muscle atrophy.



Fig.2: Depicting exaggerated lumbar lordosis and winging of scapula



Fig.3: Depicting EMG showing myopathic pattern

Discussion

Facioscapulohumeral Muscular Dystrophy (FSHD) is a relatively uncommon disorder characterized by autosomal dominant inheritance. This means that inheriting just one copy of the defective gene from one

parent is adequate to cause the condition. Typically, FSHD manifests during adolescence, though symptoms may be apparent earlier in childhood. Initially, muscle weakness may be uneven, and individuals with milder forms of the disease may not even realize they are affected. However, FSHD can progress over time, with approximately 15-20% of patients eventually requiring wheelchair assistance, and a small fraction may necessitate ventilatory support as the condition advances.

In the case described, a 30 Yrs old male presented with weakness in the face and arms. Notably, there was no family history of the condition, indicating that this particular case was sporadic rather than inherited.

FSHD may also present with additional features such as mild sensorineural hearing loss and vascular retinopathy, although these manifestations are not consistent among all affected individuals, and their relationship to the genetic abnormality underlying FSHD remains unclear.

Overall, this passage provides an in-depth overview of FSHD, covering its clinical presentation, associated features, and the variability in its progression and presentation among individuals.

Conclusion

Facioscapulohumeral Muscular Dystrophy (FSHD) is a rare muscle disorder that should be considered in children displaying muscle weakness. It's crucial not to mistake it for oculopharyngeal muscular dystrophy, which typically manifests much later in life, usually between the ages of 40 and 60.

Currently, there is no specific treatment available for FSHD. However, scapular stabilization procedures have demonstrated efficacy in improving scapular winging, a common symptom associated with the condition.

Given the absence of definitive treatment options, the primary focus should be on providing comprehensive counseling to both the parents and patients regarding the nature of the disease, its anticipated progression, and available strategies for managing symptoms to enhance overall quality of life. Physiotherapy remains the mainstay strengthening therapy for limb and facial muscle weakness.

References

1. Tawil R. facioscapulohumeral muscular dystrophy curr. Neurol Neurosci Rep 2004;4:51-54
2. Tonini M.M, Passos - Bueno MR, Cerqueira A, et al Asymptomatic Carriers and gender differences in FSHD. Neuromuscul Disord 2004; 14:33-38
3. Tupler R, Gabellini D. Molecular Basis of FSHD. Cell Mol life Sci 2004;61:557-66
4. Davies KE, Nowek KJ. Molecular mechanism of muscular dystrophies: Old and new players. Nat Rev Mol Cell Biol 2006;7:762-66
5. Tyler FH, Stephens FE. Studies in disorders of muscle: II: Clinical manifestations and inheritance of FCHD in large family. Ann Intern Med 1950; 32:640-52
6. Tawil R, Figlewicz DA, Griggs RC, et al. FSHD, A distinct regional myopathy with a novel molecular pathogenesis. Ann Neurol 1998; 43:279-81
7. Wehlgemuth M, Vander Kooi El VanKestern RG, et al. Ventilatory support in FSHD. Neurology 2004;63:176-78
8. Vande Maarel SM. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta 2007; 189:697-702